publication date: Mar. 6, 2020

NCI Trials

NCI Trials for March 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10317

A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center LAO

Mims, Alice Scott

(614) 685-6031

 

Phase I – 10324

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum – Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Grisham, Rachel Nicole

(646) 888-4653

 

Phase I – FOR0003

A Phase I Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma

Duke University Medical Center

Randazzo, Dina Marie

(919) 613-3712

 

Phase II – ARST1921

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

Children’s Oncology Group

Navid, Fariba

(323) 361-5418

 

Phase II – S1900B

A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

SWOG

Elamin, Yasir Y.

(713) 792-3428

 

Phase III – NRG-GU008

Randomized Phase III Trial … Continue reading NCI Trials for March 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.